0000000000591961

AUTHOR

Guiomar Bautista

showing 2 related works from this author

Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transpla…

2020

The net impact of cytomegalovirus (CMV) DNAemia on overall mortality (OM) and nonrelapse mortality (NRM) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a matter of debate. This was a retrospective, multicenter, noninterventional study finally including 749 patients. CMV DNA monitoring was conducted by real-time polymerase chain reaction (PCR) assays. Clinical outcomes of interest were OM and NRM through day 365 after allo-HSCT. The cumulative incidence of CMV DNAemia in this cohort was 52.6%. A total of 306 out of 382 patients with CMV DNAemia received preemptive antiviral therapy (PET). PET use for CMV DNAemia, but not the occurrence of CMV DNAemia, taken …

Oncologymedicine.medical_specialtybone marrowinfection and infectious agents - viralmedicine.medical_treatmentCongenital cytomegalovirus infectionCytomegaloviruscomplicationHematopoietic stem cell transplantation030230 surgerylaw.inventionCell therapy03 medical and health sciences0302 clinical medicinelawInternal medicinehemic and lymphatic diseasesRisk of mortalityImmunology and AllergyMedicineHumansTransplantation HomologousPharmacology (medical)Cumulative incidencePolymerase chain reactionRetrospective StudiesTransplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesmedicine.diseasepracticeTransplantationinfectious infection and infectious agents - viral: Cytomegalovirus (CMV) [bone marrow/hematopoietic stem cell transplantation clinical research/practice complication]infectiousclinical researchCohortCytomegalovirus InfectionsDNA Viralhematopoietic stem cell transplantationCytomegalovirus (CMV)business
researchProduct

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia

2017

We retrospectively compared the clinical outcomes of adults with acute leukemia who received single-unit umbilical cord blood (UCB) transplantation (sUCBT) (n = 135) or stem cell transplant using coinfusion of a UCB graft with CD34+ cells from a third-party donor (Haplo-Cord) (n = 72) at different institutions within the Grupo Espanol de Trasplante Hematopoyetico. In multivariable analysis, patients in the Haplo-Cord group showed more rapid neutrophil (hazard ratio [HR], 2.3; 95% confidence interval [CI], 1.5-3.3; P < .001) and platelet recovery (HR, 1.6; 95% CI, 1.2-2.3; P = .015) and lower incidence of chronic graft-versus-host disease (GVHD) (relative risk, 0.5; 95% CI, 0.3-0.8; P = .01)…

Acute leukemiamedicine.medical_specialtyendocrine systemTransplantationbusiness.industryHazard ratioMyeloid leukemiaContext (language use)Hematologymedicine.diseaseUmbilical cordGastroenterologyTransplantation03 medical and health sciencesLeukemia0302 clinical medicinemedicine.anatomical_structureGraft-versus-host disease030220 oncology & carcinogenesisInternal medicineImmunologyMedicinebusiness030215 immunology
researchProduct